chartexchange

NKGen Biotech to Present Long-Term Follow-Up of Troculeucel in Moderate Alzheimer’s Disease at CTAD 2026

GlobeNewswire Inc. | Nov 9, 2026 8:05 AM EST

SANTA ANA, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present a poster at the 19 th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, taking place November 16-19, 2026, in Boston, Massachusetts, and virtually.

Read original article